Literature DB >> 3032883

In-vitro activity of erythromycin, roxithromycin and CP 62993 against common paediatric pathogens.

S C Aronoff, C Laurent, M R Jacobs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3032883     DOI： 10.1093/jac/19.2.275

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  12 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 2.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; C Thornsberry; T L Gavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

4.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 5.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

6.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 7.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

8.  In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans.

Authors:  R Pajukanta; S Asikainen; M Saarela; S Alaluusua; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 9.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

10.  Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media.

Authors:  N Principi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.